Inhibition of oxytocin-induced uterine activity in midpregnancy by combined adrenergic  -blockade and  -stimulation.
D000032:Abortion, Therapeutic; D000293:Adolescent; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000328:Adult; D000765:Anesthesia, Conduction; D000773:Anesthesia, Obstetrical; D000431:Ethanol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008012:Lidocaine; D009638:Norepinephrine / Q000009:adverse effects / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D010121:Oxytocin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010646:Phentolamine / Q000009:adverse effects / Q000627:therapeutic use*; D010902:Pituitary Gland / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D013566:Sympathomimetics / Q000009:adverse effects / Q000627:therapeutic use*; D014599:Uterus / Q000187:drug effects* / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D013566:Sympathomimetics; D000431:Ethanol; D010121:Oxytocin; D008012:Lidocaine; D009638:Norepinephrine; D010646:Phentolamine